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Abstract
Exploring the re-emergence of embryonic signaling pathways may reveal important information for cancer biology.
Nodal is a transforming growth factor–β (TGF-β)–related morphogen that plays a critical role during embryonic devel-
opment. Nodal signaling is regulated by the Cripto-1 co-receptor and another TGF-β member, Lefty. Although these
molecules are poorly detected in differentiated tissues, they have been found in different human cancers. Poor
prognosis of glioblastomas justifies the search for novel signaling pathways that can be exploited as potential thera-
peutic targets. Because our intracranial glioblastoma rat xenograft model has revealed importance of gene ontology
categories related to development and differentiation,we hypothesized that increased activity of Nodal signaling could
be found in glioblastomas. We examined the gene expressions of Nodal, Cripto-1, and Lefty in microarrays of invasive
and angiogenic xenograft samples developed from four patients with glioblastoma. Protein expression was evaluated
by immunohistochemistry in 199 primary glioblastomas, and expression levels were analyzed for detection of correla-
tionswith available clinical information. Gene expression ofNodal, Lefty, and Cripto-1was detected in the glioblastoma
xenografts. Most patient samples showed significant levels of Cripto-1 detected by immunohistochemistry, whereas
only weak to moderate levels were detected for Nodal and Lefty. Most importantly, the higher Cripto-1 scores were
associated with shorter survival in a subset of younger patients. These findings suggest for the first time that Cripto-1,
an important molecule in developmental biology, may represent a novel prognostic marker and therapeutic target in
categories of younger patients with glioblastoma.
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Introduction
Glioblastomas are highly invasive primary brain tumors with a largely
unknown etiology that are difficult to surgically eradicate [1,2]. The
therapeutic effects of radiation and the cytotoxic drug temozolomide,
the routinely used treatment today, are limited, as glioblastomas
inevitably recur and most patients die within 2 years of diagnosis
[3–9]. To improve prognosis, increased biologic knowledge, more dif-
ferentiated diagnostics, and novel therapeutic strategies are needed.
Deregulated embryonic developmental features are suggested to
be involved in cancer initiation and progression. The expression of
morphogens, signaling molecules that govern the formation and dif-
ferentiation of tissues and organs, during development is precisely
regulated and controlled by specific mediators and cues from the en-
vironment that includes temporal and spatial expression of effectors
and inhibitor molecules. In cancer, the balance of regulators may be
disrupted and lead to aberrant expression of pluripotency-associated
genes and proteins [10]. Aggressive tumor cells may therefore show
characteristics similar to embryonic progenitors [11]. Furthermore, cell
fate regulation in embryonic development and oncogenic activity in
several cancers seems to share common signaling pathways [12–14].
Several tumor types are now suggested to be initiated and main-
tained by stem-like cells having capacity for self-renewal, propagation,
and potential for multilineage differentiation [15,16]. Cancer stem-like
cells seem to be resistant to conventional therapy and are believed to
contribute to recurrence after therapy [17,18]. In addition, a high pro-
portion of stem-like cells and also “stemness” signatures in different
tumors have been associated with poorer clinical outcome [19–23].
Exploring in cancer the re-emergence of signaling pathways that are
active in normal stem cell self-renewal should have the potential to
increase tumor biology knowledge and thus open areas to deduce
new therapeutic targets. The Nodal pathway is one of the signaling
pathways shown to be required for the maintenance of undifferentiated
embryonic stem cells [24–27]. Nodal is an embryonic morphogen that
belongs to the transforming growth factor–β (TGF-β) superfamily. It
is involved in the formation of different germ layers (embryonic cell
layers) and influences the establishment of the left-right axis of different
organ systems in the body [28–30]. Nodal signaling can be regulated by
cofactors such as the epidermal growth factor–like member Cripto-1
and another TGF-β member Lefty. More specifically, Nodal ligand
can bind to the Cripto co-receptor and a complex of type I and type II
activin receptors (ALK4/7 and ActRIIB) and trigger phosphoryla-
tion events that can activate Smad2/3 and facilitate binding to Smad4
[31]. Human Cripto-1, also defined as teratocarcinoma-derived growth
factor 1, is a cell membrane protein that can be secreted [32,33]. Lefty
functions as an antagonist of the Nodal signaling pathway [34]. Nodal,
Lefty, and Cripto-1 are critical for early embryonic development but
poorly detected in normal adult tissues. However, an increased expres-
sion of both Nodal and Cripto-1 has been detected in different human
tumors [11,32,33,35–38].
Our group has developed a human glioblastoma xenograft model
that characterizes essential aspects of the disease. Multicellular spheroids
from patient biopsies are generated and implanted intracranially in
nude rats. The model reflects highly invasive and prominent angio-
genic glioblastoma characteristics, where non-angiogenic tumors can
switch to angiogenic tumors after serial in vivo intracranial passaging
[39,40]. This model has also revealed the importance of gene ontology
(GO) categories connected to development and differentiation as well as
chemoresistant characteristics associated with an infiltrative stem-like
phenotype [41].
Knowing the poor prognosis and limited effect of the current treat-
ment in glioblastomas, we aim to contribute to development of
increased pathobiologic understanding and to unravel potential targets
for glioblastoma therapy. As there is increased evidence for similarities
between features of embryonic development and factors involved in
tumor initiation and progression, we hypothesized that increased ac-
tivity in the Nodal signaling pathway could be found in glioblastomas.
To evaluate this, we analyzed GO categories related to development
and examined the gene expression of the morphogen Nodal and its
related genes Cripto-1 and Lefty in the xenograft model. We also
evaluated potential clinical relevance by analyzing the association
between the protein expression of these molecules and patient sur-
vival. Our findings suggest for the first time that Cripto-1, an impor-
tant molecule in developmental biology, may represent a novel
prognostic marker and therapeutic target in categories of younger
patients with glioblastoma.
Materials and Methods
Tissue Culture
Tumor fragments were obtained at surgery from patients with
glioblastoma. The collection of tumor tissue was approved by the
Regional Ethics Committee at Haukeland University Hospital (Bergen,
Norway). The patients gave their informed consent to specimen col-
lection. Biopsy spheroids were prepared as described previously [42].
Briefly, biopsy tissue were minced by surgical blades and transferred to
agar-coated flasks containing standard tissue culture serum-supplemented
medium. Such spheroid cultures are suggested to induce limited selec-
tion of cells compared to neurosphere cultures in serum-free medium
[43]. After 1 to 2 weeks in culture, spheroids with diameters between
200 and 300 μm were selected for intracerebral implantation [40].
In Vivo Experiments
Biopsy spheroids were stereotactically implanted into the right brain
hemisphere of nude rats as described earlier [40,44,45]. Tumor growth
was monitored using an MRI Magnetom Vision Plus 1.5T T scanner
(Siemens, Erlangen, Germany) and a small loop finger coil as previously
described [46]. The animals were killed when symptoms developed,
and the brains were removed. The tumors were excised, and new
spheroids were generated and transplanted into new animals [39,40].
Brains were also fixed in 4% formaldehyde, or tissues were snap frozen
in liquid N2 for further studies. All procedures were approved by the
National Animal Research Authority (Oslo, Norway).
Gene Expression Analysis
Total RNA was extracted using the RNeasy Midi Kit (Qiagen
GmbH, Hilden, Germany), and cDNAs and labeled cRNAs were
generated as previously described [47,48] using the Applied Biosystems
Chemiluminescent RT-IVT Labeling Kit (Applied Biosystems, Foster
City, CA). The Applied Biosystems Human Genome Survey Micro-
array, Chemiluminescence Detection Kit, and Applied Biosystems
1700 Chemiluminescent Microarray Analyzer were used according to
the manufacturer’s instructions for ABI1700 DNA oligonucleotide
microarrays (37k). Hybridizations were performed for corresponding
low- and high-generation tumors from four patients. The resulting files
from the image processing software were imported into the analysis
software J-Express [49] (http://jexpress.bioinfo.no). Array data are
available in the public repository ArrayExpress (http://www.ebi.ac.uk/
arrayexpress; Accession No. E-MTAB-1185; Table W1). Controls,
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flagged spots, and weak spots (S/N < 3) were removed. All arrays were
quantile normalized. Similar samples have previously been analyzed by
two additional microarray platforms (Agilent Technologies 16k cDNA
and 44k oligonucleotide arrays) and by real-time quantitative polymer-
ase chain reaction [39]. Overrepresentation statistics of GO categories
were calculated on the ranked gene list produced by a paired signifi-
cance analysis of microarrays of data from low- and high-generation tu-
mor samples. The top 1000 differentially expressed genes of the 18,269
present in total in the normalized data set was used as a representative
top list to investigate for overrepresentation of GO categories, using a
Fisher’s exact test as implemented in J-Express.
Patient Material and Histopathology
Tumor biopsies originated from patients with glioma undergoing
surgery at Haukeland University Hospital in the period from 1998 to
2008. Formalin-fixed and paraffin-embedded tissue specimens from
243 glioma biopsies were available. Hematoxylin and eosin–stained
sections for all patients were examined, without knowledge of the
clinical course, to verify the glioblastoma diagnosis (World Health
Organization grade IV) according to the World Health Organization
classification [50]. The patients gave their written informed consents
to specimen collection, and the ethical board in Norway approved
the study.
Tissue Microarray and Immunohistochemistry
Cylinders, 1 mm in diameter, were punched from representative
areas of the tumors and mounted in recipient paraffin blocks using a
standard precision instrument (Manual Tissue Arrayer MTA-1; Bee-
cher Instruments, Inc, Sun Prairia, WI). A total of 729 cylinders
were mounted, three representative samples of most tumors in addi-
tion to control samples from human tonsil, liver, gray matter, white
matter, glioblastoma, and medulloblastoma. Five-micrometer-thick
sections were prepared from the tissue microarray blocks and stained
with hematoxylin and eosin to confirm that the specimens were suit-
able for immunohistochemical evaluation.
Five-micrometer-thick, formalin-fixed, paraffin-embedded tissue
sections were also prepared for immunohistochemistry, carried out
on a Microm HMS 710i Automated Immunostainer (Thermo Fisher
Scientific/Richard-Allan Scientific, Fremont, CA). Briefly, following
antigen retrieval (citrate buffer, pH 6.0) and blocking steps (H2O2,
avidin, biotin, and Background Sniper for 10 minutes each), sections
were incubated in mouse anti-human Nodal antibody (Abcam, Cam-
bridge, MA; ab55676) in 1:50 dilution for 60 minutes, followed by
biotinylated goat anti-mouse IgG secondary antibody (Biocare Medi-
cal, LLC, Pike Lane Concord, CA; GM601H) and then streptavidin-
peroxidase (Thermo Fisher Scientific Lab Vision, TS-125-HR) for
20 minutes. For the Cripto-1 detection, sections were incubated in
rabbit anti-human Cripto-1 (teratocarcinoma-derived growth factor 1)
antibody (Rockland, Gilbertsville, PA; 600-401-997) in 1:400 dilu-
tions for 55 minutes followed by biotinylated goat anti-rabbit IgG
secondary antibody (Biocare Medical, LLC; GR602 H). For the Lefty
detection, sections were incubated in goat anti-Lefty (M-20) polyclonal
antibody (Santa Cruz Biotechnology, Inc, Santa Cruz, CA; sc-7408) in
1:50 dilutions for 60 minutes followed by biotinylated mouse anti-goat
IgG secondary antibody (Biocare Medical, LLC; MG610 H). Color
was developed with 3,3′-diaminobenzidine substrate (Thermo Scien-
tific Lab Vision, TA-125-HDX), and sections were counterstained with
hematoxylin (Biocare Medical, LLC; NM-HEM). As negative controls,
adjacent serial sections were incubated with ChromPure mouse, rabbit,
or goat IgG (Jackson ImmunoResearch Laboratories, West Grove,
PA; ChromPure Mouse IgG 015-000-003, ChromPure Rabbit IgG
011-000-003, and ChromPure Goat IgG 005-000-003) at the same
concentration as the primary antibodies.
After staining, the specimens were evaluated semiquantitatively
and blinded for the follow-up/clinical data by a method developed
and validated in melanomas [51]. As the molecules analyzed are
both cell surface localized and secreted into the surrounding matrix,
the overall staining of the entire tissue was evaluated and given the
following expression scores: negative (0), weak (1), moderate (2),
and strong (3). A minimum of two spots from each patient was
represented, and the highest staining score from each patient was
chosen. The protein expression scores were also categorized in the
following two groups: low expression (scores 0-1) and high expression
(scores 2-3).
Statistics
A filter to select only the primary glioblastomas (tumors developed
from lower grade and recurrent tumors were not included) was used,
and frequency analyses of age, age classes, and protein expression
were performed. The overall survival time (observation days) was de-
fined as the time from operation to death (postoperative survival
time) or to a censored time point for the eight patients still alive (cen-
sored survival time). Univariate survival data and curves were esti-
mated by the Kaplan-Meier method [52] using the log-rank test
[53] for disclosing differences between categories of each variable
(gender, age classes, and different protein score groups). Variables
were further analyzed by use of the Cox proportional hazards model
[54]. To assess associations of variables to survival time, a backward
stepwise selection process was used to identify a final multiple Cox
proportional hazards regression model. The significance level was set
at P ≤ .05. All statistical calculations were conducted using the
Statistical Package for the Social Sciences (SPSS) software (PASW
Statistics 18.0).
Results
Gene Expression in the Xenograft Model
We have earlier reported that GO categories connected to devel-
opmental aspects and negative regulators of differentiations are re-
vealed in our glioblastoma xenograft model especially in the highly
invasive phenotype [41]. Further evaluation of the analysis of statis-
tical overrepresented GO categories from the top 1000 differential
expressed genes in the paired significance analysis of microarrays
from low (highly invasive)– and high (highly angiogenic)–generation
tumor samples notified that 5 of the 51 GO categories with a
P value < .05 were morphogenesis categories (data not shown).
As a follow-up, we examined the gene expression of the morpho-
gen Nodal and the related genes Cripto-1 and Lefty in the highly in-
vasive and in the highly angiogenic tumors developed after serial
intracranial passaging. Nodal, Cripto-1, and Lefty were found ex-
pressed in both the invasive and angiogenic phenotypes. When com-
paring gene expression intensity in the two phenotypes, the Nodal
gene expression intensity was found decreased in three of four pa-
tients in the highly angiogenic phenotype compared to the invasive
phenotype (Figure 1A). The expression of the co-receptor Cripto-1
gene was found slightly increased in the angiogenic phenotype in a
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similar number of patients (Figure 1B). Furthermore, the decrease in
Nodal expression in the highly angiogenic tumors corresponded with
an increase in the expression of its inhibitor Lefty in samples from
two of the patients (Figure 1C ). Our findings suggest potential roles
for these genes in glioblastomas. However, glioblastomas are known
to be highly heterogeneous, and microenvironmental interplay and
epigenetic changes may influence the expression of specific genes
and proteins. To study the potential functional and clinical relevance
of these genes, we examined the protein expression of Nodal, Cripto-1,
and Lefty in samples from 243 patients with glioblastoma.
Patient Samples and Protein Expression
We wanted to assess the protein expression of our genes of interest
in a cohort as homogeneous as possible. We therefore chose to exclude
the patients with recurrent tumors and tumors developed from lower
grade. Of the 243 glioma patient biopsies examined, the 199 pa-
tients with primary glioblastoma were selected. Only these patients,
115 males and 84 females, were included in the following analyses.
The age range was 30 to 84 years, and the median age at operation
was 65 years. The numbers of patients in different age classes are
given in Table 1. Median postoperative survival time was 259 days
(37 weeks/8.6 months). There was no significant difference between
males (277 days) and females (229 days) in median survival time
(log-rank test P value = .439).
Protein expression of Nodal, Lefty, and Cripto-1 was assessed by
immunohistochemistry on formalin-fixed and paraffin-embedded
tissue microarray specimens (Figure 2). A variable expression of the
different proteins examined was found in the primary glioblastoma
specimens (Figure 3). The molecules analyzed in this study are both
cytoplasmic and cell surface localized and also secreted into the
surrounding matrix, revealing a rather diffuse staining pattern. The
staining pattern was homogeneous within the tumor tissue in most
samples, but the staining intensity varied between the different
patients. Overall, a negative-to-weak expression of Nodal and Lefty
and a stronger expression of Cripto-1 were found in these tumors
(Figure 4). The study demonstrated moderate-to-strong expression
of Cripto-1 protein in more than 50% of the primary glioblastomas
examined, and only 4% were negative for this protein. In contrast,
we could only verify a moderate expression of Nodal in 6% of the
patients. Lefty was found moderately expressed in one patient and
strongly expressed in another.
We also asked whether high or low expression of any of the three
markers co-associates with high or low expression of any of the other
two. Both patients with high Lefty expression had a low Nodal expres-
sion and a high Cripto-1 expression. (This might suggest a possible
inhibitory effect of Lefty on Nodal expression in these two patients.)
When selecting for patients with high (scores 2-3) Nodal expression,
there were 12 patients with expression score 2 (no patient had a Nodal
expression score 3). Eight of these patients had a high (scores 2-3)
Cripto-1 expression (four score 2 and four score 3), and all had a
low (scores 0-1) Lefty expression.
In conclusion, protein expression studies of the important Nodal
signaling molecules Nodal, Lefty, and Cripto-1 revealed convincing
importance of Cripto-1, possibly independent of Nodal and Lefty in
our glioblastoma patient cohort.
Protein Expression, Age, and Survival
To investigate if specific protein expression categories were asso-
ciated with survival time, univariate survival analysis (Kaplan-Meier
method) was performed. The protein expression scores were catego-
rized in two groups, low (scores 0-1) and high (scores 2-3) expression.
We were unable to reveal any significant association between protein
expression and postoperative survival time in non-stratified analyses
Figure 1. Gene expression of Nodal (A), Cripto-1 (B), and Lefty (C) in samples from highly invasive versus angiogenic phenotypes
in glioblastoma xenografts developed from four (1-4) glioblastoma patient biopsies. The diagrams illustrate log2-transformed gene
expression intensity. The data were extracted from globally normalized (quantile normalization) microarray data. ArrayExpress Data Archive
and corresponding patient sample codes are given in Table W1. The expression levels of Nodal, Lefty, and Cripto-1 are in the range of 0.3 to
0.7 compared to the levels of housekeeping genes such as glyceraldehyde-3-phosphate dehydrogenase (GAPDH) and actin, beta (ACTB).
Table 1. Age and Sex Distribution of 199 Patients with Primary Glioblastoma Operated at Hauke-
land University Hospital in the Period from 1998 to 2008.
Frequency Percentage
Sex
Male 115 57.8
Female 84 42.2
Age at operation in years*
30 to 39 6 3.0
40 to 49 19 9.5
50 to 59 40 20.1
60 to 69 76 38.2
70 to 79 47 23.6
80 to 89 11 5.5
*Median, 65 years; range, 30 to 84 years.
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of observation days by low/high protein expression categories of
Nodal, Lefty, or Cripto-1 (Table 2).
There was a significant influence of age in non-stratified sur-
vival analysis (log-rank test P value < .001). When stratified for
age (<60 and ≥60), patients <60 years had a significantly longer
(107 days) median postoperative survival when they expressed low
levels of Cripto-1 compared to high levels (log-rank test P value =
.044). In contrast, for patients ≥60 years, no significant differ-
ences related to differential Cripto-1 expression was shown (P =
.597). For patients below 50 years, the difference in median sur-
vival was 242 days (8 months; P = .013) in favor of Cripto-1 low-
expressing tumors.
Both continuous age and age decades had a significant effect on
postoperative survival time of the patients with glioblastoma, and the
Cox regression analyses revealed interaction effect of age and Cripto-1
expression on survival (P = .006) (Table 3). The table expresses that
10 years increased age reduces the hazard ratio for high Cripto-1 by
a factor of 0.63 as also shown in the corresponding Cox regression
Figure 2. Examples of immunostaining showing moderate (2) Nodal intensity staining (A) and strong (3) Lefty (C) and Cripto-1 (D) staining
and a negative control IgG (B) in human glioblastoma biopsy sections. The arrowhead points to a mitotic cell in the specimen stained
for Cripto-1.
Figure 3. Different degrees of protein expression of Nodal, Lefty, and Cripto-1 in human glioblastomas. Nodal: scores 0 (A), 1 (B), and
2 (C). Negative control IgG (D). Lefty: scores 0 (E), 1 (F), 2 (G), and 3 (H). Cripto-1: scores 0 (I), 1 (J), 2 (K), and 3 (L).
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plots in Figure 5. These results showed a worse effect on survival with
high Cripto-1 in younger patients compared to older patients.
No additional significant associations could be added by looking
at different combinations of protein expression of the respective
molecules Nodal, Cripto-1, or Lefty.
Discussion
In this study, we report, for the first time, considerable levels of
Cripto-1 in more than 50% of the patients in a glioblastoma cohort
including 199 primary tumors. In contrast, Nodal and its inhibitor
Lefty exhibited very limited protein expression in these samples. The
study revealed that younger patients with glioblastoma with high
Cripto-1 protein expression were associated with a significantly shorter
postoperative median survival compared to patients in the same
age range with low Cripto-1 expressing tumors. The expression of
Cripto-1, known to be important in maintaining stem cell pluri-
potency, and its association with age and survival are new and surprising
findings in glioblastoma that can contribute to the identification of
young patients with potentially worse prognosis than other young
patients with glioblastoma, who, in general, have a more favorable
prognosis after diagnosis compared to older patients.
Cripto-1 in Human Tumors
Cripto-1, known as a co-receptor for the TGF-β–related morphogen
Nodal, is shown to play important roles in embryonic development
and tumor progression [55]. Expression of Cripto-1 mRNA and/or
protein has been found in human tumors including colorectal, breast,
gastric, pancreatic, ovarian, and lung carcinomas [32,33] as well as in
uveal [56] and cutaneous melanomas [57]. Interestingly, high levels
of Cripto-1 have been associated with aggressive clinicopathologic
features and poor prognosis in colorectal, gastric, and breast cancers
[58–60]. The proportion of patients with Cripto-1–positive glio-
blastoma found in this study is comparable to those reported for other
cancers [61].
Potential Nodal-Independent Mechanisms of Cripto-1
in Glioblastomas
To our knowledge, protein expression and side-by-side comparison
of the expression of both Nodal and Cripto-1 in a large homogeneous
diagnosed tumor patient cohort have not earlier been evaluated. Al-
though other studies have indicated a role for Nodal in brain tumor
invasion [36] and angiogenesis [62], our study showed a considerable
protein expression of Cripto-1 and very limited expression of Nodal
and Lefty in the tumors, suggesting a potential functional role for
Cripto-1 independent of Nodal and Lefty in primary glioblastomas.
It is known that Cripto-1 can act as a cofactor for Nodal and inter-
act with Nodal signaling at different levels [32], but it has also been
shown to act as a growth factor independent of Nodal [63–65].
For instance, Cripto-1 can activate mitogen-activated protein kinase
and Akt pathways independently of Nodal by directly binding to a
membrane-associated heparan sulfate proteoglycan, glypican-1 [64],
or to the heat shock glucose-regulated protein (GRP78) [66–68]. The
binding can phosphorylate the tyrosine kinase c-Src, which in turn
can trigger Nodal-independent pathways that influence epithelial-to-
mesenchymal transition, migration, and invasion as well as proliferation
and survival [32,64,69].
Although c-Src is suggested to be required for Cripto-1 activation
of mitogen-activated protein kinase and Akt, immunohistochemical
staining of glioblastoma biopsy specimens from our patients could not
verify whether Cripto-1 signaling is occurring through these pathways
Figure 4. Numbers of patients with glioblastoma with different
scores of Nodal, Lefty, and Cripto-1 protein expression. nrs denotes
non-representative specimen/staining for evaluation.
Table 2. Frequency and Postoperative Survival of Patients with Primary Glioblastoma with Low and High Protein Expression Categories.
Protein Expression Number of Patients Percentages of Patients Median Survival Estimate (Days) SE 95% CI Log-Rank Test P Value
Nodal .595
Low (scores 0-1) 161 80.9 241 26.1 (190.0, 292.0)
High (scores 2-3) 12 6.0 285 13.0 (259.5, 310.5)
Missing 26 13.1
Lefty .162
Low (scores 0-1) 174 87.4 259 28.2 (203.7, 314.3)
High (scores 2-3) 2 1.0 86
Missing 23 11.6
Cripto-1 .161
Low (scores 0-1) 61 30.7 259 54.1 (153.0, 365.1)
High (scores 2-3) 110 55.3 242 35.9 (171.6, 312.4)
Missing 28 14.1
Univariate survival analyses (Kaplan-Meier method) of 199 patients operated at Haukeland University Hospital in the period from 1998 to 2008.
SE indicates standard error; CI, confidence interval.
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(data not shown). However, this does not rule out the involvement of
Cripto-1 in alternative signaling pathways [68].
Cripto-1 and Angiogenesis
Cripto-1–induced enhancement of migration, invasion, prolifera-
tion, and survival functions has been shown in epithelial cells, car-
cinoma, sarcoma, melanoma, and endothelial cells, indicating a role
for Cripto-1 also as an angiogenic molecule in the formation of vas-
cular structures in tumors [33,57,70,71]. Cripto-1 expression can be
regulated by hypoxia-inducible factor-1a, and it has therefore been
suggested that hypoxic conditions in tumors may trigger Cripto-1 ex-
pression that can contribute to increased tumor vascularization [72].
Glioblastomas are highly invasive and angiogenic tumors. In our
xenograft model, we are able to study the distinct characteristic pheno-
types. Interestingly, we observed slight increased Cripto-1 gene expres-
sion intensity in the animal angiogenic phenotype, indicating a possible
contribution of Cripto-1 in glioblastoma angiogenesis. It would be
interesting to determine the stage at which Cripto-1 would contrib-
ute to tumor angiogenesis in glioblastoma. In our patient cohort, the
association between evolution of tumor angiogenesis and Cripto-1
levels could not be determined since the tumor samples were already
highly vascularized.
Molecular Classification of Glioblastomas and
Targets for Treatment
Heterogeneous glioblastoma populations (including both primary
and secondary glioblastomas as well as some grade III tumors) have
recently been found to cluster into four molecular subtypes, namely,
proneural, neural, classic and mesenchymal, based on gene expression
profiles [73,74]. Although these molecular subclasses predict prognosis
and show different treatment responses, no specific targeted treatments
Figure 5. Illustration of decreasing effect on survival of high Cripto-1 protein expression score with increasing age. Survival functions and
hazard ratios were estimated from 171 patients with primary glioblastoma, who were operated at Haukeland University Hospital in the
period from 1998 to 2008, by a Cox regression model with interaction term between age and Cripto-1 score (likelihood test P = .006).
The Cox regression plots illustrate the survival for individuals with the age of 40, 50, 60, and 70 years, respectively, as estimated by the
Cox regression model.
Table 3. Results from Cox Regression of 171 Patients with Primary Glioblastoma Operated at
Haukeland University Hospital in the Period from 1998 to 2008.
HR 95% CI LR Test P Value
Age/10 years (continuous) 2.01 (1.53, 2.64) <.001
Cripto-1 .006
Low (scores 0-1) 1.00 Reference
High (scores 2-3) 18.85 (2.20, 161.26)
Cripto-1 high × age/10 0.63 (0.45, 0.88) .006
HR indicates hazard ratio; CI, confidence interval; LR, likelihood ratio.
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have yet been suggested. In a more treatment-focused perspective, a
stem cell–related “self-renewal” signature associated with resistance
to concomitant chemotherapy in glioblastomas has been reported
and suggested as a guide to future therapy and marker development
for individualized treatment [17]. In that respect, the increased
GRP78 mRNA expression found to be involved in chemoresistance
and inversely correlated with survival in glioblastomas [75] is of inter-
est, especially since Cripto-1/GRP78 interaction has been suggested to
regulate this novel pathway in stem cell and cancer stem cell activities
[76,77]. Approaches to target Cripto-1 expression or function should
therefore become attractive for glioblastomas.
Inhibition of Cripto-1
On the basis of the known properties of Cripto-1 as having a critical
role during early embryogenesis in stem cell renewal and pluripotency
and to be expressed both in stem-like and angiogenic cancer pheno-
types, targeting Cripto-1 could have the potential to eliminate both
differentiated tumor cells and an undifferentiated subpopulation of
cancer stem-like cells suggested to be important in tumor initiation
and self-renewal [37]. Cripto antibodies repress tumor cell growth
[78–80], and a humanized antibody is now being evaluated in a phase
I clinical trial in cancer patients (NCT 00674947). To prepare for
intracranial in vivo studies, and because we have detected Cripto-1–
positive neurons (data not shown), potential unfavorable effects in
normal tissue of inhibiting Cripto-1 protein expression have to be
considered. In fact, Cripto has been indicated to have an important
role in preventing neuronal differentiation in embryonic stem cells
[81] and has been suggested as a target for improving embryonic
stem cell–based therapy in Parkinson’s disease [82,83]. These find-
ings support that inhibition of Cripto-1 also in patients with brain
tumors can be appropriate even with the existence of Cripto-1–
positive neurons, because increased neuronal differentiation should
be a desired effect.
Summary and Future Prospects
In our study, statistical considerations revealed a significant age-
related association between expression of the pluripotency factor
Cripto-1 and survival. These results suggest that Cripto-1 protein ex-
pression in younger patients with primary glioblastoma may represent
a novel negative prognostic marker and a potential therapeutic target in
these patients. Our work underline the necessity of examining a large
number of patients to find and evaluate potential targets with clinical
impact in glioblastomas, tumors that reveal some common morpho-
logic features, but also show genetic and molecular heterogeneity to
a large extent. Given the role of Cripto-1 in embryonic stem cells,
glioblastoma cells in younger patients may retain a higher level of
plasticity compared to older patients, which could translate into in-
creased responsiveness to Cripto-1–dependent effects, such as prolifera-
tion, angiogenesis, and epithelial-to-mesenchymal transition. Here, we
report a potential clinical important finding that warrants further
studies, where survival in a larger group of younger aged patients with
glioblastoma should be evaluated on the basis of Cripto-1 gene and pro-
tein expression, O6-methylguanine-DNA methyltransferase methyla-
tion status, performance score, and treatment to verify Cripto-1 as a
therapeutic target that could influence patient outcome. In addition,
possible biologic samples to scrutinize specific biologic mechanisms
behind clinical differences should be obtained to design the most effec-
tive inhibitors. The use of appropriate tumor material and models will
be crucial for delineating clinical important mechanisms, where devel-
opment of tailored therapy for specific subgroups of patients requires
models that reflect both the genomics and proteomics of the tumors
and also mimic the microenvironment present.
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Table W1. ArrayExpress Data Archive and Corresponding Patient Sample Codes.
ArrayExpress Sample Codes Corresponds to
Pat_17_Gen_1 Invasive phenotype xenograft from patient 1
Pat_17_Gen_4 Angiogenic phenotype xenograft from patient 1
Pat_22_Gen_1 Invasive phenotype xenograft from patient 2
Pat_22_Gen_3 Angiogenic phenotype xenograft from patient 2
Pat_8_Gen_1 Invasive phenotype xenograft from patient 3
Pat_8_Gen_4 Angiogenic phenotype xenograft from patient 3
Pat_N_Gen_1 Invasive phenotype xenograft from patient 4
Pat_N_Gen_4 Angiogenic phenotype xenograft from patient 4
